Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BP1001 + Dasatinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BP1001||Prexigebersen||Prexigebersen (BP1001) is a liposome-incorporated antisense oligo targeting the Grb2 mRNA that inhibits Grb2 expression, resulting in growth inhibition in tumor cells (PMID: 29550383).|
|Dasatinib||Sprycel||BMS-354825||ABL Inhibitor (pan) 8 BCR-ABL Inhibitor 25 BTK inhibitor 22 CSF1R Inhibitor 23 DDR1 Inhibitor 8 DDR2 inhibitor 7 KIT Inhibitor 50 PDGFR Inhibitor (Pan) 27 SRC Inhibitor 29 TNK2 Inhibitor 6||Sprycel (dasatinib) is an inhibitor of the SRC-family of protein kinases, BCR-ABL, and ABL, and has additional activity against other kinases including KIT, DDR1/2, PDGFRA/B, and EPHA2, which prevents cell growth (PMID: 25709401, PMID: 25284748, PMID: 18797457, PMID: 23942795). Sprycel (dasatinib) is FDA approved for both Philadelphia chromosome positive adult and pediatric chronic myelogenous leukemia and adult acute lymphoblastic leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02923986||Phase Ib/II||BP1001 + Dasatinib||Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS||Withdrawn|